Interview with Jean-Luc Bélingard, CEO, Ipsen France
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US).
2015 has been Ipsen´s best year since becoming a publicly traded company, marked by their take-off in the US. In 2016 the US will overtake France to become their number one affiliate. Besides an excellent 2015 operating performance, sales grew by more than 10% year-on-year, driven by the successful launch of Somatuline in neuroendocrine tumors in the US and Europe, and the performance of Dysport in aesthetics. Core operating income grew by close to 24%, reflecting continuous transformation and cost monitoring efforts.
Contact
Address: 65 Quai Georges Gorse 92100, Boulogne-Billancourt,France
Tel: +33 (0)1 58 33 50 00
Web: http://www.ipsen.com/en/ipsen-worldwide
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Thierry Drilhon, president of the Franco-British Chamber of Commerce, talks about Brexit, the pro-industry Macron government and his positive outlook on the future of France and Franco-British cooperation. I…
David Kimelfeld, president of Lyon Métropole, speaks out about his plans for the region in terms of industrial innovation and sustainability, describing how Lyon’s historical roots would represent and enhance…
Jean Monin, general manager of Amgen France, discusses the challenges of bringing products to market in France and what is needed to better promote biosimilars. He also talks about his…
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Since 1978, Alban Muller has been a point of reference for natural ingredients in cosmetics, pharma and nutraceuticals. In this interview, Mr. Muller, founder and CEO, explains the strategic role…
Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars association), provides her take on the state of the generics and biosimilars industry in France.…
Maurice-Pierre Planel, president of the CEPS (Comité économique des produits de santé), details how the French government is unique in the way that they engage in drug pricing and comments…
Oliver Brandicourt, Sanofi’s CEO has kept his promise to steer the company back on the path to growth. This change in fortune comes after the French Pharma giant suffered losses…
As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In…
Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions…
Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our…
Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of…
See our Cookie Privacy Policy Here
